SCHEMBL23973135

SCHEMBL23973135

O=c1[nH]c(C2(Cc3ccccc3)CC2)nc2c1CNCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 10/20 0.51
TNKS O95271 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
HTR2B P41595 4/20 0.41
HTR2A P28223 3/20 0.41
HPGD P15428 1/20 0.39
PKM P14618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PARP1 P09874 1/20 0.37
CYP2D6 P10635 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
VCP P55072 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR7 P34969 1/20 0.35
ADRA1A P35348 1/20 0.35
DRD3 P35462 1/20 0.35
HTR6 P50406 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23972481 0.80 HTR2C (0.44) HTR2CTNKSTNKS2HTR2BHTR2A
SCHEMBL23973129 0.78 HTR2C (0.43) HTR2CTNKSTNKS2HTR2BHTR2A
SCHEMBL23972779 0.77 HTR2C (0.43) HTR2CTNKSTNKS2PARP1
SCHEMBL23973239 0.76 TNKS (0.41) HTR2CTNKSTNKS2HTR2BHPGD
SCHEMBL23973342 0.76 HTR2C (0.42) HTR2CTNKSTNKS2HTR2BHTR2A
SCHEMBL34464429 0.75 TNKS (0.40) HTR2CTNKSTNKS2HTR2BHTR2A
SCHEMBL14344503 0.75 MTHFD2 (0.49) HTR2CTNKSTNKS2HTR2BHTR2A
SCHEMBL23972239 0.75 TNKS (0.41) HTR2CTNKSTNKS2HTR2BHTR2A
SCHEMBL23973332 0.74 MAPT (0.41) HTR2CTNKSTNKS2HTR2BHTR2A
SCHEMBL23972365 0.73 HPGD (0.38) HTR2CTNKSTNKS2HTR2BHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 HTR2C 123/4885TNKS 1079/4885TNKS2 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.